Medtronic Inc (MDT-N) Stock Predictions - Stockchase
WATCH LIST
72
Medtronic Inc (MDT-N)

ON STOCKCHASE SINCE Feb 2001

Pacemakers

biotechnology/pharmaceutical

Medtronic Inc

MDT-N

23 watching          
Join the Discussion

Medtronic Inc (MDT-N) SAVE Mar, 26, 2019, 12:03 am

90.62 0.23 (0.25%)

What the experts are saying about MDT-N



  • All
  • Filtered
Signal Opinion Expert
BUY
Medtronic Inc(MDT-N) 

December 3, 2018

Likes it very much. Thought bought Covidien, a medical device maker, a few years back. They're executing very well, such as their diabetes franchise which boosted their guidance recently to 5.5% growth in 2019. Valuation good at 17.5x vs. peers. Many of their products are essential services which is anothe tailwind.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Likes it very much. Thought bought Covidien, a medical device maker, a few years back. They're executing very well, such as their diabetes franchise which boosted their guidance recently to 5.5% growth in 2019. Valuation good at 17.5x vs. peers. Many of their products are essential services which is anothe tailwind.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$98.750
Owned Owned
Yes

PAST TOP PICK
Medtronic Inc(MDT-N) 

September 18, 2018

(A Top Pick November 13, 2017. Up 24%). He owned this as a diversified play on the medical device market. He sold the stock when it reached $90 and used the proceeds to buy Boston Scientific instead.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick November 13, 2017. Up 24%). He owned this as a diversified play on the medical device market. He sold the stock when it reached $90 and used the proceeds to buy Boston Scientific instead.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Murray

CEO & Chie, The Murray Wealth Gr...

Price Price
$96.880
Owned Owned
Yes

WEAK BUY
Medtronic Inc(MDT-N) 

May 9, 2018

He likes medical device manufacturers.  It seems they are taking market share in a booming market.  They are well diversified.  The company continues to put up great numbers. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He likes medical device manufacturers.  It seems they are taking market share in a booming market.  They are well diversified.  The company continues to put up great numbers. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$84.060
Owned Owned
No

BUY
Medtronic Inc(MDT-N) 

March 21, 2018

Likes this. One of the most dominant medtech companies, diversified from hips and knees to cardio. Good 15x forward earnings and a stable dividend yield. It's an economy of scale game in medtech, and MDT is well-positioned. Great
balance sheet and growth profile.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Likes this. One of the most dominant medtech companies, diversified from hips and knees to cardio. Good 15x forward earnings and a stable dividend yield. It's an economy of scale game in medtech, and MDT is well-positioned. Great
balance sheet and growth profile.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$80.040
Owned Owned
Unknown

COMMENT
Medtronic Inc(MDT-N) 

January 31, 2018

A dividend aristocrat, gradually increasing the dividend every year. They are in medical devices. Any increase in surgery, hospital time and heart disease would be an upside for this story. It’s been a relative laggard for the group, but has been a very good performer longer-term, and has rewarded shareholders very well. Sees this as a mutual fund of device companies.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A dividend aristocrat, gradually increasing the dividend every year. They are in medical devices. Any increase in surgery, hospital time and heart disease would be an upside for this story. It’s been a relative laggard for the group, but has been a very good performer longer-term, and has rewarded shareholders very well. Sees this as a mutual fund of device companies.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Darren Sissons

Vice Presi, Campbell Lee & Ross...

Price Price
$85.890
Owned Owned
Yes

HOLD
Medtronic Inc(MDT-N) 

January 11, 2018

Medical devices.  A good global name.  He has been bullish on medical devices for quite some time.  He has shifted that down recently because it was getting close to his break points.  Earnings were ratcheted down because of hurricane noise because of Puerto Rican noise.  IHI-N is the US ETF he would use to take positions in this sector.  You want to get through this next quarter.  You have good metrics.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Medical devices.  A good global name.  He has been bullish on medical devices for quite some time.  He has shifted that down recently because it was getting close to his break points.  Earnings were ratcheted down because of hurricane noise because of Puerto Rican noise.  IHI-N is the US ETF he would use to take positions in this sector.  You want to get through this next quarter.  You have good metrics.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$85.730
Owned Owned
Unknown

TOP PICK
Medtronic Inc(MDT-N) 

November 13, 2017

This does stuff mainly related to cardiovascular, diabetes, spinal implants and a lot of neurology stuff. The stock has been bouncing between $90 and $75. Has 4%-5% earnings growth. Dividend yield of 2.3%. (Analysts’ price target is $90.)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This does stuff mainly related to cardiovascular, diabetes, spinal implants and a lot of neurology stuff. The stock has been bouncing between $90 and $75. Has 4%-5% earnings growth. Dividend yield of 2.3%. (Analysts’ price target is $90.)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Murray

CEO & Chie, The Murray Wealth Gr...

Price Price
$79.200
Owned Owned
Yes

COMMENT
Medtronic Inc(MDT-N) 

October 13, 2017

This has certainly had its good days. It’s been quite a good company for many years. He likes the medical technology space.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This has certainly had its good days. It’s been quite a good company for many years. He likes the medical technology space.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Matt Kacur

President, FSA Financial Scienc...

Price Price
$78.070
Owned Owned
Unknown

PAST TOP PICK
Medtronic Inc(MDT-N) 

May 23, 2017

(A Top Pick May 25/16. Up 7%.) He really likes the medical device space. If he were to buy something today, he would probably buy a Stryker (SYK-N). The nice thing about devices is that it is not completely dependent on insurance pays. If you would like the whole sector, you can buy the ETF IHI-N.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick May 25/16. Up 7%.) He really likes the medical device space. If he were to buy something today, he would probably buy a Stryker (SYK-N). The nice thing about devices is that it is not completely dependent on insurance pays. If you would like the whole sector, you can buy the ETF IHI-N.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$84.610
Owned Owned
No

WEAK BUY
Medtronic Inc(MDT-N) 

April 24, 2017

They have struggled over the most recent years after being a darling.  There is the question of how healthcare will be paid for in the US.  Device companies have the hardest headwinds.  They are also in a very competitive area.  It is not expensive and is a perfectly good way to be in the health care area.  Their struggles may mean they have more upside potential if the healthcare sector improves.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They have struggled over the most recent years after being a darling.  There is the question of how healthcare will be paid for in the US.  Device companies have the hardest headwinds.  They are also in a very competitive area.  It is not expensive and is a perfectly good way to be in the health care area.  Their struggles may mean they have more upside potential if the healthcare sector improves.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Liz Miller

President, Summit Place Financi...

Price Price
$80.650
Owned Owned
Unknown

PAST TOP PICK
Medtronic Inc(MDT-N) 

April 19, 2017

(A Top Pick May 13/16. Up 2%.) The leading medical device company. He owns it because they have a plethora of products right across the range. They had a bit of an earnings hit in the 3rd quarter, and he bought more. He has a $92 target on this.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick May 13/16. Up 2%.) The leading medical device company. He owns it because they have a plethora of products right across the range. They had a bit of an earnings hit in the 3rd quarter, and he bought more. He has a $92 target on this.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Murray

CEO & Chie, The Murray Wealth Gr...

Price Price
$80.320
Owned Owned
Yes

DON'T BUY
Medtronic Inc(MDT-N) 

April 6, 2017

There has been some major earnings volatility around this one recently.  So he has backed off.  They have a mid- to high- single digit earnings growth rate, but you are paying twice that.  The PE to growth rate is too high.  You are paying top dollar for the growth you are getting.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

There has been some major earnings volatility around this one recently.  So he has backed off.  They have a mid- to high- single digit earnings growth rate, but you are paying twice that.  The PE to growth rate is too high.  You are paying top dollar for the growth you are getting.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$80.220
Owned Owned
Unknown

COMMENT
Medtronic Inc(MDT-N) 

February 22, 2017

This has everything you can think of that is tools related, from your head all the way down to your toes; cardiovascular, stent. The dominant player in medical technologies. Trading at 17X next year’s earnings. Had a hiccup last quarter, but all they had to do was show that things were back on track. He likes this.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This has everything you can think of that is tools related, from your head all the way down to your toes; cardiovascular, stent. The dominant player in medical technologies. Trading at 17X next year’s earnings. Had a hiccup last quarter, but all they had to do was show that things were back on track. He likes this.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$79.620
Owned Owned
Yes

PAST TOP PICK
Medtronic Inc(MDT-N) 

January 25, 2017

(A Top Pick Oct 11/16. Down 9.87%.) For the most part of 2016, there was a rotation out of Pharma and into medical devices. Great company, well-established and a good yield.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Oct 11/16. Down 9.87%.) For the most part of 2016, there was a rotation out of Pharma and into medical devices. Great company, well-established and a good yield.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Dean Orrico

President, Middlefield Capital ...

Price Price
$74.490
Owned Owned
Yes

COMMENT
Medtronic Inc(MDT-N) 

October 17, 2016

He likes healthcare “devices”, because it is the area that is least likely to be attacked by a government. They are somewhat less regulated from a price standpoint. This company has very strong market share in rhythm devices. Earnings for the year should be up about 7% over last year, but should accelerate up to about 11% next year. It has consolidated between $80 and $90 going back to June. Sitting at around the 150 day moving average, so technically is in a good spot. You should see earnings accelerate going forward, which is what he cares about.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He likes healthcare “devices”, because it is the area that is least likely to be attacked by a government. They are somewhat less regulated from a price standpoint. This company has very strong market share in rhythm devices. Earnings for the year should be up about 7% over last year, but should accelerate up to about 11% next year. It has consolidated between $80 and $90 going back to June. Sitting at around the 150 day moving average, so technically is in a good spot. You should see earnings accelerate going forward, which is what he cares about.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$82.570
Owned Owned
Unknown

Showing 1 to 15 of 72 entries
Successfully Saved Company
Successfully Saved Company